Fig. 5
Clinical significance of PARD3, as revealed by multiplex IHC of a tissue microarray. (A) KM survival curve showing the prognostic value of overall PARD3 and Gli1 expression and their expression in CD133 + cells and CD133- cells. (B) Patients harbouring a high density of CD133 + cells with high PARD3 expression had the worst prognosis relative to patients in the other subgroups. (C) The levels of PARD3 and phospho-aPKC were significantly higher in CD133 + cells than in CD133- cells. (D) Representative image showing that higher expression of PARD3 was associated with higher presence of CD133 + stem like cancer cells. (E) Correlation heatmap showing that the expression levels of PARD3/aPKC/Gli1/Sox2 were positively intercorrelated in CD133+ cells. (F) Consensus clustering tools were used to classify the 88 patients into two subtypes as determined by setting k to 2. (G) Patients in cluster 1 exhibited higher activation of PARD3/aPKC/Gli1/Sox2 in CD133+ cells, accompanied by less favourable clinicopathological features and (H) worse overall survival. *P < 0.05; **P < 0.01; ***P < 0.001; n.s., not statistically significant